
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
A. 510(k) Number:
k061970
B. Purpose for Submission:
Modification to the manufacturerâ€™s existing device including changes to a strictly mono-
biotinylated monoclonal antibody (the antibody itself remains unchanged), deletion of an
application for the Elecsys 1010 analyzer and modifications to specifications for linearity,
intra-assay and inter-assay precision.
C. Measurand:
Quantitative determination of IgE in human serum and plasma
D. Type of Test:
Immunoassay
E. Applicant:
Roche Diagnostics.
F. Proprietary and Established Names:
Elecsys IgE II immunoassay
G. Regulatory Information:
1. Regulation section:
21 CFR 866.5510, Immunoglobulins A, G, M, D and E Immunological test system
2. Classification:
Class II
3. Product code:
JHR, Radioimmunoassay, Immunoglobulins (D, E)
4. Panel:
Immunology (82)
H. Intended Use:
1. Intended use(s):
Immunoassay for the in vitro quantitative determination of immunoglobulin E in human
serum and plasma. Determination of total IgE is useful as an aid in the diagnosis of
allergic diseases.
2. Indication(s) for use:
Same as Intended Use
3. Special conditions for use statement(s):
For Prescription use only
4. Special instrument requirements:
I. Device Description:
The Elecsys IgE II immunoassay is a two step sandwich immunoassay with streptavidin
microparticles and electrochemiluminescence detection. Results are determined using a
calibration curve that is generated specifically on each instrument by a 2 point calibration and
a master curve provided with the reagent bar code.
J. Substantial Equivalence Information:
1. Predicate device name(s):
1

--- Page 2 ---
Elecsys IgE immunoassay
2. Predicate 510(k) number(s):
(K984326, K961481/A003)
3. Comparison with predicate:
K. Standard/Guidance Document Referenced (if applicable):
L. Test Principle:
Same
M. Performance Characteristics (if/when applicable):
1. Analytical performance:
a. Precision/Reproducibility:
2

--- Page 3 ---
b. Linearity/assay reportable range:
Not applicable
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
d. Detection limit:
Same
e. Analytical specificity:
Same
f. Assay cut-off:
Not applicable.
2. Comparison studies:
a. Method comparison with predicate device:
b. Matrix comparison:
Not applicable
3. Clinical studies:
a. Clinical Sensitivity:
No change.
b. Clinical specificity:
No change.
c. Other clinical supportive data (when a. and b. are not applicable):
Not applicable.
4. Clinical cut-off:
Not applicable.
5. Expected values/Reference range:
N. Software:
O. Proposed Labeling:
3

--- Page 4 ---
P. Conclusion:
The submitted information in this premarket notification is complete and supports a
substantial equivalence decision.
4